Increasing SMN expression outside of the nervous system with either splice-switching oligonucleotides [69] or adeno-associated virus (AAV) vectors [70], [71] markedly improves the phenotype and survival of SMA mice. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.